Top Ten most popular articles on Pharmafile.com this week
pharmafile | April 28, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | top ten
In response to the announcement of a UK snap election, this week saw the release of the ABPI’s 2017 General Election Manifesto, which urged the next government, whoever they may be, to strive towards the development of a “world-class NHS”. While this was certainly some of the biggest news, it was other happenings this week which proved popular with our reader, including the FDA’s crackdown on fraudulent online cancer ‘cures’, another lawsuit filed against Mylan and BMS’ General Manager’s disconcerting comments that the UK is “not a good place” to get cancer.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Japanese pharma expects 17% growth throughout 2017
Pharma companies attending CPhI Japan are expecting a 17% growth of the country’s market throughout the year, according to data collected at the event.
9. FDA condemns 14 companies selling fraudulent cancer ‘cures’ online
The FDA has struck out against a wave of companies offering cancer treatments online which fraudulently claim to be able to ‘cure’ the disease.
8. Teva launches competitors to GSK’s Advair inhaler
GSK has been anticipating competition to its Advair for two years and Teva has announced that it will be the first to introduce a competitor, after gaining approval from the FDA in January.
7. Breakthrough multiple sclerosis research sheds light on cause of the disease
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.
6. Psoriasis drug Siliq will be cheapest in class, Valeant reveals
Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a month, in an effort to undercut its rivals in the space.
5. Sanofi launches lawsuit against Mylan over “illegal business practices”
In a move that is sure to pile even more pressure onto Mylan after the company’s recent woes, Sanofi has launched an antitrust lawsuit against the US firm accusing it of engaging in anti-competitive practices.
4. Janssen acquires over 90% of Actelion
Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of its shares, according to provisional tender results.
3. Investigational ImmunoGen drug gives hope against platinum-resistant ovarian cancer
An investigational drug from ImmunoGen could prove effective in treating platinum-resistant ovarian cancer, an area of significant unmet need with limited effective treatment options.
2. Pharma industry calls for EMA relocation by June in open EFPIA letter
Heads of research from 19 of the biggest players in the industry have called for a decision to be made on the new site of the EMA’s new headquarters by June in an open letter from the EFPIA.
1. England “really is not a good place” to get cancer, BMS UK General Manager says
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to life-saving treatments on the NHS, claiming the UK is falling behind its neighbours in Europe.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
